Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.


What´s up at IZB 

Dear Mister/Miss Titel ,

After the long Corona break, we are now holding face-to-face events again: A networking meeting with Plattform Life Sciences, our IZBrunch in September and the really exciting Munich Life Science Pitch Day. Click on the videos - and you will get a wonderful insight into the new life of the IZB!

You will find many more IZB and campus news again in our latest newsletter.

With best regards

Your Dr. Peter Hanns Zobel
Managing Director IZB
6th Munich Life Science Pitch Day at the IZB with over 20 investors
The partners HTGF, Bayer AG and Boehringer Ingelheim as well as the participating venture capital firms were enthusiastic about the quality of the research. 10 start-ups had the opportunity to present their innovative drug development projects to renowned venture capital companies.  
More ...
 6th Munich Life Science PitchDay
Co-Founders & Managing Directors mk2 Biotechnologies, Dr. Marco Giuman, Dr. Sebastian Mangold, Dr. Konstantinos Antonopoulos
mk2 Biotechnolgies new start-up at the Innovation and Start-up Center Biotechnology (IZB) in Martinsried, near Munich, Germany
The goal of mk2 Biotechnologies is to apply its unique platform approach for the synthesis and purification of authentic peptides on a large scale, which can be broadly applied in various market segments.
More ...
Dr. Sabine Hauck becomes Senior VP Corporate Development of Leukocare AG
Dr. Sabine Hauck headed the R&D department at Leukocare for the last four years. “It is a great pleasure to take up the role as Senior VP Corporate Development. Since the time I joined Leukocare in 2017, my goal has always been to support the company´s development not only in terms of R&D but also on a strategic level. Thus, I am delighted to be in a position to make a decisive contribution to Leukocare´s corporate development,” said Hauck.  
More ... 		Dr. Sabine Hauck becomes Senior VP Corporate Development of Leukocare AG
Dr. Cornelius Pompe joins Leukocare AG from Amgen Research
Industry expert becomes new Vice President R&D. 
“I am very happy to join Leukocare´s management team. When I learned about Leukocare’s approach to combine bioinformatics and deep learning with best-in-class analytics to redefine formulation development, I was excited,” said Pompe.
More ...
 Dr. Cornelius Pompe joins Leukocare AG from Amgen Research
Arne Treinies new CFO and Managing Director of AMSilk
Arne Treinies new CFO and Managing Director of AMSilk
The financial expert will continue to drive the further expansion of the silk polymer manufacturer. “We are very pleased to have Arne Treinies on board as CFO. His broad experience in consulting, start-ups and as CFO of larger companies will be of great value to AMSilk in our industrial scale-up process,” said Ulrich Scherbel, CEO of AMSilk.
More ...

IZBrunch from September 23, 2021
Presenters at the IZBrunch were:

Prof. Dr. Olivia Merkel, Department of Pharmacy, LMU Munich. Topic: Inhalation therapy and prevention of respiratory virus infections with siRNA and

Ulrich Scherbel Managing Director AMSilk GmbH. Topic: Shaping the future with silk proteins for products in various industries.

More ...

 IZBrunch, September 23, 2021
First F2F event after the Corona period at the IZB: Network meeting of the Life Sciences platform
“Biotechnology has saved the world”
First F2F event after the Corona period at the IZB: Network meeting of the Life Sciences platform. Dr. Hubert Birner, Managing Partner of TVM Capital,  stated: “German biotechnology has saved the world. The VC companies have been able to raise a lot of money as a result – so a lot can be expected for the future.”
More ...
Munich doctoral students receive award for application-oriented nanosciences
Three doctoral students from Munich received this year’s Nano Innovation Award from the Center for NanoScience in August 2021. “For ibidi, CeNS is a constant source of inspiration through technological and personal exchange and an important link to the scientific community,” said Roman Zantl, Co-founder and managing director of ibidi.
More ...
 ibidi sponsort den Nano Innovation Award 2021

CAMPUS
Campus network continues to grow Campus network continues to grow
“We are very pleased about the start of construction, because this new research building will make excellent use of the synergies at the Großhadern/Martinsried site to further dovetail basic biomedical research and clinical application. Modern medicine is inconceivable without translational research,” said Professor Dr. Bernd Huber, LMU-President
More...
The MPI of Biochemistry welcomes two new research directors at the Martinsried Campus
Molecular geneticist Kikuë Tachibana and structural biologist John Briggs expand scientific expertise at the site. Tachibana heads the “Totipotency” research department. Briggs heads the department of “Viral and Cellular Structural Biology”. 
More ...
 The MPI of Biochemistry welcomes two new research directors at the Martinsried Campus



Kontakt

Susanne Simon
Leitung Presse- und Öffentlichkeitsarbeit
Tel.: 089/55 279 48-17
E-Mail: izb@izb-online.de          

Standort Martinsried:

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Standort Weihenstephan:

Fördergesellschaft IZB mbH
Lise-Meitner-Strae 30
85354 Freising/Weihenstephan


Wenn Sie diese E-Mail (an: unknown@noemail.com) nicht mehr empfangen möchten, können Sie diese hier kostenlos abbestellen.

Fördergesellschaft IZB mbH
Dr. Peter Hanns Zobel
Am Klopferspitz, 19
82152 Planegg
Deutschland

+4989552794817
info@izb-online.de